News | April 05, 2013

Argon Medical Devices Launches OptionElite Retrievable Vena Cava Filter

Company also explains acquisition of Angiotech interventional business

April 5, 2013 — Continuing its commitment to provide best-in-class medical devices for the prevention of recurrent pulmonary embolism (PE), Argon Medical Devices Inc. launched the OptionELITE Retrievable Vena Cava Filter. The OptionELITE IVC Filter, designed by Rex Medical LP, provides the clinician with the same safe and trusted design now enhanced for ease of delivery and retrievability.

"Safety and retrievability are without question two of the most vital, and rare, characteristics in a best-in-class retrievable IVC filter. Argon is pleased to be able to offer the best of these worlds by introducing the OptionELITE," stated George Leondis, president of Argon Medical Devices. "This technology provides clinicians with a safe and stable IVC filter that can be confidently deployed and retrieved while minimizing the risk of migration, penetration and fracture.  This product, along with the new Cleaner15 Mechanical Thrombectomy System, and the recently announced acquisition of Angiotech's interventional business, positively positions the company as a significant player in the interventional arena."

OptionELITE's enhanced retention anchor pattern provides stability and reduced retrieval force while preventing migration and reducing the risk of penetration. The sturdy apex design has an increased capture zone for ease of snaring. In addition, the new high performance spiral sheath remains the lowest profile IVC filter delivery system available today (6.5 French OD, 5 French ID) and has been reinforced for improved kink-resistance and pushability.

"I have used Option for many years. At Weill Cornell, we had the opportunity to participate in the OptionELITE evaluation and found the device to be just as safe and stable as the Option, with no migrations and significantly easier to retrieve," said David W. Trost, M.D., associate professor of clinical radiology, Weill Medical College of Cornell University in New York, N.Y.

Argon Medical will be featuring the OptionELITE IVC Filter at the 38th Annual Scientific Meeting of the Society of Interventional Radiology in New Orleans, La., April 13-18, 2013 and will be offering a hands-on simulator training experience at booth 840.

PE affects an estimated 600,000 to 1 million people in the United States and its incidence is increasing annually. PE is the sudden blockage of an artery in the lung (pulmonary artery) typically thrombus. Emboli dislodgement can be caused by peripheral vascular disease (PVD), severe deep vein thrombosis (DVT), trauma and prolonged immobilization often following major surgical procedures.  PE occurs when these clots break loose and embolize to block pulmonary blood vessels in the lungs. According to clinical research, if left untreated, PE has a mortality rate of 30 percent and is a leading cause of inpatient deaths in U.S. hospitals. 

For more information:

Related Content

Sentinel Cerebral Protection System Reaches 50-Center Adoption Milestone in U.S.
News | Embolic Protection Devices | February 19, 2018
Claret Medical announced that since U.S. Food and Drug Administration (FDA) clearance in June 2017, its Sentinel...
The Boston Scientific FilterWire EZ embolic protec filter system.

The Boston Scientific FilterWire EZ embolic protection system.

News | Embolic Protection Devices | October 31, 2017
October 31, 2017 — The VAMPIRE 3 study evaluated if the selective use of distal filter protection might decrease the
Claret Medical Closes $14.5 Million in Series C Financing for Sentinel Cerebral Protection System
News | Embolic Protection Devices | October 23, 2017
October 23, 2017 — Claret Medical announced that it has closed on a Series C financing of $14.5 million led by Lights
Sentinel Cerebral Protection System Significantly Reduces Stroke and Mortality in TAVR
News | Embolic Protection Devices | September 18, 2017
September 18, 2017 – Claret Medical announced publication of a new study in the...
Protembis Announces Successful First-in-Human Use of  ProtEmbo Cerebral Protection System in European Trial
News | Embolic Protection Devices | September 07, 2017
Protembis GmbH announced the first clinical applications of its ProtEmbo Cerebral Protection System to complement a...
PinnacleHealth First in Pennsylvania to Implant Sentinel Cerebral Protection System
News | Embolic Protection Devices | August 23, 2017
PinnacleHealth is the first hospital in Pennsylvania and one of the first 10 in the country to introduce new technology...
PinnacleHealth Initiates Clinical Study of TriGuard Embolic Protection Device
News | Embolic Protection Devices | April 11, 2017
Through a new clinical trial, patients at Harrisburg, Pa.-based PinnacleHealth have access to an investigational device...
Cardiogard embolic protection system for surgical valve reaplacement

The CardioGard embolic protection system for surgical aortic valve replacement.

Feature | Embolic Protection Devices | March 22, 2017
March 22, 2017 — Two U.S.
Keystone Heart, TriGuard Embolic Protection Device, real-world results, PCR London Valves Conference 2016
News | Embolic Protection Devices | September 29, 2016
Keystone Heart Ltd. recently announced the safety and efficacy of the TriGuard Cerebral Embolic Protection device...
Claret Medical, Sentinal CPS, cerebral protection system, FDA marketing application, TAVR, embolic protection
News | Embolic Protection Devices | September 20, 2016
Claret Medical announced its filing of a marketing application with the U.S. Food and Drug Administration (FDA) for...
Overlay Init